Public Company News

PharmAbcine to Participate in BIO-Europe 2021

DAEJEON, South Korea, Sept. 20, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in the 27th annual BIO-Europe which will tak...

2021-09-20 20:00 1730

Farmmi Continues Growth with Latest Order for Export to Southwest Asia

LISHUI, China, Sept. 20, 2021 /PRNewswire/ -- Farmmi, Inc. ("Farmmi" or the "Company") (NASDAQ: FAMI), an agriculture products supplier inChina, today announced the Company's subsidiary Zhejiang Farmmi Biotechnology Co., Ltd., is continuing its growth with another new product order for its popula...

2021-09-20 20:00 11799

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

* Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder * Phase 2 clinical trial on target to start by end of 2021 and expected to read out topline data by end of 2022 ADELAIDE, Australia, Sept....

2021-09-20 18:00 4284

Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

SHANGHAI, Sept. 19, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of digestive system tumors. Results of this trial have been ...

2021-09-20 08:24 9463

Cambium Networks 60 GHz cnWave Technology Enables Pentanet to Rapidly Build a Multi-Gigabit Fixed Wireless Network Serving Perth, Australia

Innovative broadband service provider delivers multi-gigabit speeds to the network edge ROLLING MEADOWS, Ill., Sept. 20, 2021 /PRNewswire/ -- Cambium Networks  (NASDAQ: CMBM), a leading global provider of wireless networking solutions, today announced thatPentanet is building neXus, a multi-gigab...

2021-09-20 06:30 13011

2021 CSCO | Henlius will Release Four Oral Presentations of Two Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar

SHANGHAI, Sept. 18, 2021 /PRNewswire/ -- The 24th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) will be held online and in-person from 25th to 29th September 2021. In this meeting, Henlius will release 4 study results of 2 products to be commercialized, the novel anti-PD-1 mAb ser...

2021-09-18 20:00 12282

Lufax Joins FTSE ESG Low Carbon Select Indexes

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Lufax Holding Ltd ("Lufax" or the "Company") (NYSE: LU), a leading technology-empowered personal financial services platform inChina, today announced that the Company will be added to the following FTSE ESG Low Carbon Select Indexes, following FTSE Russell...

2021-09-18 10:00 21979

Baidu-Backed DeepWay Unveils Smart New Energy Heavy-Duty Truck to Automate Road Freight

BEIJING, Sept. 17, 2021 /PRNewswire/ -- DeepWay, a Baidu-backed company, today unveiled Xingtu, a smart new energy heavy-duty truck with a computing power of more than 500 TOPS and ultra-long-distance sensing capabilities of more than 1 kilometer. This announcement marks Baidu's entry into the US...

2021-09-17 21:09 5343

MINISO Group Files Annual Report on Form 20-F for Fiscal Year 2021

GUANGZHOU, China, Sept. 17, 2021 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO) ("MINISO", "MINISO Group" or the "Company"), a fast-growing global value retailer offering a variety of design-led lifestyle products, today filed with the U.S. Securities and Exchange Commission its annual...

2021-09-17 20:45 18159

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of Serplulimab Injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with carboplatin and albumin-bound ...

2021-09-17 20:00 4707

InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355

BEIJING, Sept. 17, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies called Tiannuojiancheng Pharm...

2021-09-17 20:00 5641

RYB Education, Inc. Reports Second Quarter 2021 Financial Results

BEIJING, Sept. 17, 2021 /PRNewswire/ -- RYB Education, Inc. ("RYB" or the "Company") (NYSE: RYB), a leading early childhood education service provider in China, today announced its unaudited financial results for the second quarter of 2021. Second Quarter 2021 Operational and Financial Summary ...

2021-09-17 20:00 17871

RYB Education, Inc. Announces Change of Board Composition

BEIJING, Sept. 17, 2021 /PRNewswire/ -- RYB Education, Inc. ("RYB" or the "Company") (NYSE: RYB), a leading early childhood education service provider in China, today announced the resignation of Mr. Chimin Cao as the chairman of the board of directors (the "Board") of the Company and the re-desi...

2021-09-17 20:00 17831

111, Inc. Announces Participation in the Cantor Virtual Global Healthcare Conference

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that Senior Vice President, Investor Relations and...

2021-09-17 19:00 4484

Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management p...

2021-09-17 18:30 2084

"Captain Tsubasa: Dream Team" Dream Championship 2021 Online Qualifiers Kick Off Today

TOKYO, Sept. 17, 2021 /PRNewswire/ -- KLab Inc., a leader in online mobile games, announced that the Japanese and global versions ofCaptain Tsubasa: Dream Team will hold the worldwide Dream Championship 2021 tournament and will kick off its online qualifiers starting today. Additionally, special ...

2021-09-17 18:15 1964

Tarena to Report Second Quarter of 2021 Financial Results on September 24, 2021

BEIJING, Sept. 17, 2021 /PRNewswire/ -- Tarena International, Inc. (NASDAQ: TEDU) ("Tarena" or the "Company"), a leading provider of adult professional education and childhood and adolescent quality education services inChina, today announced that it will report its unaudited financial results fo...

2021-09-17 18:00 14730

The Joint Venture between ReneSola Power and Eiffel Investment Group Acquires Its First 200 MW Project Portfolio

STAMFORD, Conn., Sept. 17, 2021 /PRNewswire/ -- ReneSola Ltd ("ReneSola Power" or the "Company") (www.renesolapower.com ) (NYSE: SOL), a leading fully integrated solar project developer, today announced that European Solar Energy Development JV, the joint venture co...

2021-09-17 18:00 3270

Dada Group Launches Smart Delivery SaaS System to accelerate delivery digitalization

SHANGHAI, Sept. 16, 2021 /PRNewswire/ -- Dada Group (Nasdaq: DADA) ("DADA"), China's leading local on-demand delivery and retail platform, today announced the launch of its open digital logistics platform, Dada Smart Delivery SaaS System. Based on Dada Now's self-developed Smart Logistics System ...

2021-09-17 11:54 3241

Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

* Pre-clinical data exploring the in vitro and in vivo efficacy of BBT-176 will be disclosed via an ePoster at the ESMO Congress 2021 * Patient dosing for the phase 1/2 clinical study of BBT-176 was initiated in April 2021…the topline data of the first-in-human, dose escalation study is expec...

2021-09-17 06:00 2038
1 ... 662663664665666667668 ... 778

Week's Top Stories